Salvage treatment in recurrent endometrial cancer of the pelvis and peritoneal cavity
Sign Up to like & getrecommendations! Published in 2019 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2019.05.002
Abstract: Regional recurrence of endometrial cancer is a challenging yet potentially curable group of patients without defined standard of care. Our aim is to determine optimal methods of salvage therapy for regionally recurrent endometrial cancer. Twenty-two… read more here.
Keywords: surgery; peritoneal cavity; recurrent endometrial; cohort ... See more keywords
Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review
Sign Up to like & getrecommendations! Published in 2020 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2020.100553
Abstract: Highlights • Effective treatment options for recurrent endometrial carcinomas are limited.• Immune checkpoint inhibitor is a recent progress in cancer immunotherapy.• Reports on recurrent endometrial carcinomas managed by pembrolizumab are limited. read more here.
Keywords: immune checkpoint; regression microsatellite; recurrent endometrial; pembrolizumab ... See more keywords
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic oncology"
DOI: 10.1016/j.ygyno.2021.04.034
Abstract: OBJECTIVE We reviewed our institutional data to evaluate toxicity and efficacy outcomes of pembrolizumab/lenvatinib in recurrent endometrial cancer in a "real-world" clinical setting and to compare the impact of reduced lenvatinib starting dose on outcomes.… read more here.
Keywords: recurrent endometrial; recommended reduced; toxicity; endometrial cancer ... See more keywords
A case of recurrent endometrial cancer with long‐term complete remission following pembrolizumab‐induced severe immune‐related adverse event colitis
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Obstetrics and Gynaecology Research"
DOI: 10.1111/jog.15346
Abstract: Endometrial cancer is generally diagnosed at an early stage and has a good prognosis, although once it recurs, the prognosis is poor because of few therapeutic options. Since endometrial cancer has a high frequency of… read more here.
Keywords: endometrial cancer; recurrent endometrial; case recurrent; immune related ... See more keywords
‘Salvage cytoreductive surgery for pelvic side wall recurrent endometrial cancer: robotic combined laterally extended endopelvic resection (LEER) and laterally extended pelvic resection (LEPR) debulking’
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2022-003746
Abstract: Endometrial cancer is the most common gynecological malignancy, and most patients present at an earlystage. However, approximately 15% of confineduterus endometrial cancer patients will see their cancer return. Treatment options for recurrent endometrial cancer depend… read more here.
Keywords: endometrial cancer; recurrent endometrial; laterally extended; extended endopelvic ... See more keywords
AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.tps5608
Abstract: TPS5608 Background: Prognosis of advanced/recurrent endometrial cancer (EC) is poor with median survival of 12-15 months for patients with measurable disease. Treatment options are limited, with primary management being chemotherapy with carboplatin and paclitaxel. EC… read more here.
Keywords: recurrent endometrial; advanced recurrent; atezolizumab; trial ... See more keywords
A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6010
Abstract: 6010Background: The efficacy of treatment for recurrent endometrial cancer (EC) remains limited. Vascular endothelial growth factor and inflammatory chemokines are proangiogenic factors and immune ... read more here.
Keywords: study cabozantinib; recurrent endometrial; randomized phase; endometrial cancer ... See more keywords
Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.738370
Abstract: Objective To evaluate the efficacy and prognosis of fertility-sparing re-treatment on patients with recurrent endometrial cancer (EC) and atypical endometrial hyperplasia (AEH) who wish to preserve their uterus after complete remission (CR) for primary conservative… read more here.
Keywords: treatment; recurrent endometrial; fertility sparing; cancer atypical ... See more keywords